JP2004533825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533825A5 JP2004533825A5 JP2002582213A JP2002582213A JP2004533825A5 JP 2004533825 A5 JP2004533825 A5 JP 2004533825A5 JP 2002582213 A JP2002582213 A JP 2002582213A JP 2002582213 A JP2002582213 A JP 2002582213A JP 2004533825 A5 JP2004533825 A5 JP 2004533825A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- patient
- molecule
- cell
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 51
- 210000004027 cell Anatomy 0.000 claims 28
- 101001096065 Homo sapiens Plexin domain-containing protein 1 Proteins 0.000 claims 17
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 claims 17
- 102100037891 Plexin domain-containing protein 1 Human genes 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 238000012360 testing method Methods 0.000 claims 15
- 230000033115 angiogenesis Effects 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 10
- 210000002889 endothelial cell Anatomy 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 230000009134 cell regulation Effects 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 208000030761 polycystic kidney disease Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 238000013169 thromboelastometry Methods 0.000 claims 3
- 238000004627 transmission electron microscopy Methods 0.000 claims 3
- 101100425732 Mus musculus Tnmd gene Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000009149 molecular binding Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108091005703 transmembrane proteins Proteins 0.000 claims 2
- 102000035160 transmembrane proteins Human genes 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28285001P | 2001-04-11 | 2001-04-11 | |
| US35426202P | 2002-02-06 | 2002-02-06 | |
| PCT/US2002/008253 WO2002083874A2 (en) | 2001-04-11 | 2002-04-10 | Endothelial cell expression patterns |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004533825A JP2004533825A (ja) | 2004-11-11 |
| JP2004533825A5 true JP2004533825A5 (cg-RX-API-DMAC7.html) | 2005-12-22 |
Family
ID=26961707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002582213A Pending JP2004533825A (ja) | 2001-04-11 | 2002-04-10 | 内皮細胞発現パターンの評価法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7393932B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1572867B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004533825A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002258543B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2443995C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002083874A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090233270A9 (en) * | 2000-08-02 | 2009-09-17 | St Croix Brad | Secreted and cytoplasmic tumor endothelial markers |
| ATE360071T1 (de) * | 2000-12-05 | 2007-05-15 | Wisconsin Alumni Res Found | Rezeptor für ein toxin aus bacillus anthracis |
| CN1832965B (zh) * | 2003-03-04 | 2011-03-02 | 麒麟麦酒株式会社 | 内皮细胞特异性抗体及其用途 |
| EP1690932A4 (en) * | 2003-10-20 | 2008-03-05 | Teijin Pharma Ltd | ASSOCIATED WITH BONE AND / OR GAP DISEASES GEN |
| WO2006029045A2 (en) * | 2004-09-03 | 2006-03-16 | Kirin Brewery Co., Ltd. | Endothelial cell specific antibodies and uses thereof |
| WO2006091326A1 (en) * | 2005-01-28 | 2006-08-31 | Attogen Inc. | Anti-prl-3 antibodies and methods of use thereof |
| AU2007317753B2 (en) | 2006-11-09 | 2013-11-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Differential gene expression in physiological and pathological angiogenesis |
| WO2008101118A2 (en) | 2007-02-14 | 2008-08-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates |
| CA2731296A1 (en) * | 2008-07-18 | 2010-01-21 | Centre National De La Recherche Scientifique | New mutated netrin 4 proteins, fragments thereof and their uses as drugs |
| US9290556B2 (en) | 2008-09-29 | 2016-03-22 | The Trustees Of The University Of Pennsylvania | Tumor vascular marker-targeted vaccines |
| WO2010071938A1 (en) * | 2008-12-24 | 2010-07-01 | Commonwealth Scientific And Industrial Research Organisation | Novel collagen constructs |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
| JP2014524902A (ja) | 2011-06-14 | 2014-09-25 | アメリカ合衆国 | Ｔｅｍ８抗体、そのコンジュゲートおよびそれらの使用 |
| KR101358810B1 (ko) * | 2011-12-30 | 2014-02-11 | 한국원자력의학원 | 방사선 피폭 진단용 마커 ｉｇｆｂｐ-5, 그 마커의 발현수준을 측정하는 방사선 피폭 진단용 조성물, 그 조성물을 포함하는 방사선 피폭 진단용 키트, 및 그 마커를 이용한 방사선 피폭을 진단하는 방법 |
| CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| AU2001283062A1 (en) * | 2000-08-02 | 2002-02-13 | The Johns Hopkins University | Endothelial cell expression patterns |
-
2002
- 2002-04-10 US US10/474,794 patent/US7393932B2/en not_active Expired - Lifetime
- 2002-04-10 JP JP2002582213A patent/JP2004533825A/ja active Pending
- 2002-04-10 WO PCT/US2002/008253 patent/WO2002083874A2/en not_active Ceased
- 2002-04-10 CA CA2443995A patent/CA2443995C/en not_active Expired - Lifetime
- 2002-04-10 AU AU2002258543A patent/AU2002258543B2/en not_active Expired
- 2002-04-10 EP EP02728495.9A patent/EP1572867B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6196338B2 (ja) | 診断および治療のための腫瘍関連抗原の同定 | |
| JP2004533825A5 (cg-RX-API-DMAC7.html) | ||
| JP2007537197A5 (cg-RX-API-DMAC7.html) | ||
| JP2005500039A5 (cg-RX-API-DMAC7.html) | ||
| KR100707315B1 (ko) | 세포주기의 ｇ2/ｍ 상전이에 필수적인 ｈｉｖ-1 ｖｐｒ에대한 세포 수용체 | |
| ES2627962T3 (es) | Productos génicos de expresión diferencial en tumores y su uso | |
| JP2010248210A (ja) | 疾患のイメージング、診断、及び治療 | |
| JP2007506417A5 (cg-RX-API-DMAC7.html) | ||
| JP2006518991A5 (cg-RX-API-DMAC7.html) | ||
| JP2008508861A5 (cg-RX-API-DMAC7.html) | ||
| Dmitrenko et al. | Reduction of the transcription level of the mitochondrial genome in human glioblastoma | |
| CN116322750A (zh) | 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法 | |
| US8664359B2 (en) | Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets | |
| Wong et al. | Induction of the interleukin-2/15 receptor β-chain by the EWS–WT1 translocation product | |
| EP1604009A2 (en) | Method for identifying risk of melanoma and treatments thereof | |
| JP4383170B2 (ja) | ヒストン脱アセチル化酵素９ | |
| JP2011504361A (ja) | 肝細胞癌細胞に特異的なペプチドおよびその適用 | |
| CA2446327A1 (en) | A polypeptide and dna thereof useful as a neovascular marker | |
| JP2008514925A (ja) | 腫瘍を検出し且つ治療するための組成物及び方法 | |
| US20080089895A1 (en) | Use of T-cell immune response cDNA 7 (TIRC7) in angiogenic and anti-angiogenic therapy | |
| US20160176936A1 (en) | Mps peptides and use thereof | |
| US20160074428A1 (en) | Compositions and methods for the treatment of human immunodeficiency virus infection | |
| CN100571785C (zh) | Annexin A3与癌症的铂类化疗药物耐药性的相关性 | |
| WO2009150491A2 (en) | Interferon epsilon (ifne1) as a marker for targeted cancer therapy | |
| JP4975444B2 (ja) | 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法 |